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httpicense.Abstract Poor aqueous solubility of chemical entities presents a major challenge to modern drug
delivery, because of their low bioavailability. Our aim was to prepare and evaluate a suitable solid
self-emulsifying drug delivery system (SSEDDS) as a potential carrier for rutin. After screening of
various vehicles (surfactants, co-surfactants and oils) and selection of those having the better drug
solubilizing power, liquid SEDDS were formulated. Prepared formulations were evaluated for self-
emulsifying ability and phase diagrams were constructed to optimize the systems. System (S6), pre-
pared from Triton/Acconon/Labrafac, attained highest drug solubilization capacity, hence, was
selected for the preparation of SSEDDS by adsorption on different nano-structured carriers (Neusi-
lin, Fujicalin and F-melt) in different ratios. S6 had a very small particle size of
4.849 ± 0.001 nm and a high percentage transmittance of 99.31 ± 0.16%. SSEDDS showing good
ﬂow properties as well as reasonable drug loading capacity were selected for in vitro drug release
studies. The SSEDDS (SS4) composed of Neusilin US2: S6 (1:2) attained the best drug release
properties and was subjected to further characterization (SEM, FTIR and XRD). Conclusion:
The optimized liquisolid dosage form of rutin provided good ﬂowability as well as fast drug release
properties and, therefore, can be suitable for oral delivery system.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Many drug candidates display low solubility in water, which
leads to poor bioavailability, high intrasubject/intersubject113639193, +20 233335456;
m (R. Kamel).
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://dx.doi.org/10.1016/j.bfopcu.201variability and lack of dose proportionality. Hence, oral deliv-
ery of numerous drugs, including rutin, is hindered owing to
their high hydrophobicity.1,2 Therefore, producing suitable
formulations are essential to improve the solubility and bio-
availability of such drugs. Rutin is a polyphenolic compound
having diverse pharmacological activities including antialler-
gic, anti-inﬂammatory,3 vasoactive, antitumor, antibacterial,
antiviral and anti-protozoal properties,4 hypolipidaemic, cyto-
protective, antispasmodic and anticarcinogenic effects.5 Its
poor solubility in aqueous media is the reason for its poor bio-
availability. Oral administration is desired for the administra-
tion of rutin as nutritional supplement in a dose of 60 mg to be
taken three times daily.2,6aculty of Pharmacy, Cairo University.
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262 R. Kamel, M. BashaOne of the most popular and commercially viable formula-
tion approaches for solving the problems of low oral bioavail-
ability is self-emulsifying drug delivery systems (SEDDS).
SEDDS have been shown to be reasonably successful in
improving the oral bioavailability of poorly water-soluble
drugs.7 SEDDS, which belong to lipid-based formulations,
are isotropic mixtures of drug, oil/lipid, surfactant, and/or
co-surfactant, which form ﬁne emulsion/lipid droplets, ranging
in size from approximately 100 nm to <50 nm, on dilution
with physiological ﬂuid. The drug, therefore, remains in solu-
tion in the gut, avoiding the dissolution step that frequently
limits the absorption rate of hydrophobic drugs from the crys-
talline state.8 Presence of the surfactant in the microemulsion
structure, being dispersed in the gastric content, will allow a
portion of the added surfactants to be located at the O/W
interface. Therefore, the concentration of the free surfactant
in the emulsion water phase is probably much lower than its
nominal concentration in the entire emulsion, thus decreasing
the toxic effect attributed to the free surfactant.9
Traditional preparation of SEDDS is normally present as
liquids, the preparation technique involves dissolution of drugs
in oils and their blending with suitable solubilizing agents.
However, this technique has some disadvantages, for example,
low stability, difﬁcult portability, and few choices of dosage
forms. Irreversible drugs/excipients precipitation may also be
problematic.10 More importantly, the large quantity (30–
60%) of surfactants in the formulations can induce gastroin-
testinal (GI) irritation. To address these problems, solid SED-
DS (SSEDDS) have been investigated, as alternative
approaches. Such systems require the solidiﬁcation of liquid
self-emulsifying (SE) ingredients into powders/nanoparticles
to create various solid dosage forms.11 Thus, SSEDDS com-
bine the advantages of SEDDS (i.e. enhanced solubility and
bioavailability) with those of solid dosage forms (e.g. low pro-
duction cost, convenience of process control, high stability and
reproducibility, and better patient compliance).
Free ﬂowing powders may be obtained from liquid SEDDS
by adsorption onto solid carriers. A signiﬁcant beneﬁt of the
adsorption technique is the good content uniformity.12 Liqui-
solid systems are composed of a non-volatile, water miscible li-
quid vehicle, solid drug particles, and selected excipients,
namely the carrier. The liquid portion, which can be a liquid
drug, a drug suspension, or a drug solution in suitable non-vol-
atile liquid vehicles, is incorporated into the porous carrier
material. Thus, an apparently dry, free ﬂowing, and compress-
ible powder is obtained.13Stability studies with liquisolid sys-
tems containing various drugs14 showed that storage at
different conditions neither had an effect on their ﬂow nor re-
lease properties. This indicates that the technology is a prom-
ising technique for release enhancement, which is not
associated with any physical stability issues. Besides drug re-
lease enhancement, the liquisolid approach is a promising tech-
nique because of the simple manufacturing process as well as
low production costs.13
However, it is very important to search for more efﬁcient
excipients which have higher adsorption capacities and faster
drug release to improve liquisolid formulations. Fortunately,
it is interesting that there are some recent pharmaceutical
excipients which have nano-structures15 like F-melt, Fujica-
lin and Neusilin US2.16,17 These are low density, porous
carriers with a high surface area.Some previous studies were aiming to improve rutin bio-
availability2,6,18; however, this is the ﬁrst study focusing on this
type of delivery systems.
The aim of this study was to investigate SEDDS as a poten-
tial drug delivery system for the poorly water soluble drug
rutin. Several oils, surfactants (S) and co-surfactants (CoS)
were screened for their rutin solubilizing power. Different
blends of the best solubilizing S, CoS and oils were done to ob-
tain an optimized SEDDS. The selected SEDDS were charac-
terized and adsorbed on three different nano-structured
carriers (F-melt, Fujicalin and Neusilin), then the inﬂu-
ence of these solid carriers on drug dissolution and SSEDDS
ﬂow properties was investigated.
2. Materials and Methods
2.1. Materials
Rutin was a kind gift from Kahira Pharmaceutical and Ind.
Co., Cairo, Egypt. Labrasol (PEG-6 caprylic/capric triglyc-
erides), Plurol Oleique CC 497 (polyglyceryl-3 dioleate),
Labrafac PG (propylene glycol dicaprylocaprate), Capryol
90 (propylene glycol monocaprylate) and Labraﬁl M 1944
LS (decyl polyglucoside) were gift samples from Gattefosse´,
France. Simulosol 1292DF was supplied from SEPPIC,
France. Capmul MCM C8 (glyceryl monocaprylate), Acco-
nonMC8-2 EP/NF (polyoxyethylene (8) caprylic/capric gly-
cerides) and Captex 200 (propylene glycol dicaprylocaprate)
were obtained as gift samples from ABITEC Corporations,
Cleveland, USA. Miranol C2 M was provided by Rhodia
Inc, USA. Poly ethylene glycol 400, propylene glycol, Diace-
tin, methyl laurate, isopropyl myristate, isopropyl palmitate,
oleic acid, Triton X-100 (polyoxyethylene (10) octylphenyl
ether) and ethanol were purchased from Sigma Chemical Com-
pany, St. Louis, USA. Miglyol 812 (caprylic/capric triglycer-
ide) was kindly provided by Sasol Germany GmbH, Witten,
Germany. Neusilin US2, F-melt type M and Fujiculin
were gifted from Fuji Chemical Industry CO., Ltd. (Toyama,
Japan). All other chemicals used were of analytical grade.
2.2. Screening study
To select the oils, surfactants (S) and co-surfactants (coS) hav-
ing the highest solubilizing capacity of the drug, screening of
the different components was carried out. As a preliminary
experiment, drug solubility was determined qualitatively by vi-
sual observation of solution transparency and presence of any
drug crystals.19,20 Brieﬂy, 10 mg of drug and increasing quan-
tities of the tested components in 10 ml glass vials were shaken
at 100 rpm in a controlled temperature water bath at
37 ± 1 C (Memmert Gmgh, Germany) to facilitate the solu-
bilization. The solubility of the drug was observed visually
and the amount needed to give a clear solution when seen with
the naked eye under normal light was recorded.
2.3. Preparation of SEDDS
A series of SEDDS formulations were prepared using the com-
ponents selected from the screening study with the surfactant:
co-surfactant to oil (S/CoS/oil) ratio was equal to 80:10:10.
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S) followed by the addition of oil in screw capped glass vials.
The produced blends were then stirred continuously by vortex
mixing (JULABO Labortechnik, Germany) and left to equili-
brate for 24 h at ambient temperature to obtain a homogenous
isotropic mixture. The SEDDS formulations were stored at
ambient temperature until further use.
2.4. Assessment of self-emulsiﬁcation
The ﬁrst step toward the formulation of SEDDS is to deter-
mine the feasibility of being self-emulsiﬁed upon dilution. In
order to evaluate the self emulsifying properties of the SEDDS
formulations, one gram of each formulation was added drop-
wise into a beaker containing 20 ml of distilled water main-
tained at 37 ± 0.5 C stirred using a magnetic stirrer at
100 rpm. The process of self-emulsiﬁcation was assessed visu-
ally as reported and the appearance of the produced emulsions
was evaluated using the following grading.21,22
A: Denoting the rapid formation of a clear nanoemulsion
(within 1 min.).
B: Denoting the formation of a translucent nanoemulsion.
C: Represent the formation of a less clear emulsion which
had a bluish white appearance.
D: Denoting the formation of a bright white emulsion (sim-
ilar in appearance to milk).
E: Denoting the formulations which exhibited either poor
emulsiﬁcation with large oil droplets on the surface or the
emulsion was not formed.
2.5. Construction of ternary phase diagram
Phase diagrams identifying the self emulsifying region were
constructed for Type A emulsions. Ternary diagrams of sur-
factants, co-surfactants, and oil were plotted; each of them
representing an apex of the triangle. Ternary mixtures with
varying compositions of surfactant, co-surfactant, and oil were
prepared. Various combinations of surfactant, co-surfactant,
and oil were prepared. The prepared systems were visually
analyzed for any phase separation under storage for 72 h at
ambient temperature. The compositions were evaluated for
nanoemulsion formation by diluting one part of pre-concen-
trate with deionized water (1:20). The nanoemulsion regions
in the diagrams were plotted, and the wider region indicated
better self-nanoemulsiﬁcation efﬁciency.23
Based on the obtained diagrams, appropriate concentra-
tions of surfactant, co-surfactant and oil were selected for fur-
ther investigation.
2.6. Assessment of rutin solubility in the selected systems
An excess amount of rutin was added to the screw-capped test
tubes containing 4 ml of the selected systems and then stirred
for 5 min by a vortex mixer. The mixtures were then shaken
in an isothermal water bath shaker at 37 ± 1 C for 72 h
(Memmert Gmgh, Germany). After reaching equilibrium, each
tube was centrifuged at 9000 rpm for 60 min, ﬁltered through a
0.2 lm Millipore membrane ﬁlter, appropriately diluted with
methanol and then the amount of rutin was determined spec-trophotometrically at 357.5 nm (Shimadzu UV spectropho-
tometer, 2401/PC, Japan).
2.7. Characterization of rutin SEDDS
Depending on rutin solubility in the prepared systems, the
formulation with the highest drug solubilization capacity was
selected for characterization and further investigation. Rutin-
loaded SEDDS formulation was prepared by dissolving rutin
(maximum amount entrapped based on a previous solubility
study) in the formed SEDDS (20 g) by stirring at 40 C till a
clear, transparent system was produced which was then stored
at ambient temperature for 48 h before investigations.
2.8. Droplet size determination
The average droplet size and its distribution of the produced
rutin-loaded SEDDS were measured using a Zetasizer Nano-
ZS (Malvern Instruments, UK). SEDDS was diluted with a ra-
tio of 1:10 (v/v) with distilled water. The measurement was
done at 25 C.2.9. Percentage transmittance (kmax, 560 nm)
A total of 1 mL of SEDDS formulation was diluted 100 times
with deionized water. Percentage transmittance was measured
spectrophotometrically (Shimadzu UV spectrophotometer,
2401/PC, Japan) at 560 nm using deionized water as a blank.23
2.10. Preparation of rutin liquisolid powders
Liquisolid powders or solid SEDDS (SSEDDS) were produced
by adding rutin loaded SEDDS formulation dropwise to the
following adsorbents: Neusilin US2, F-melt type M and
Fujiculin, where SEDDS/adsorbent weight ratio varied be-
tween 1:3, 1:2, 1:1, 2:1 and 3:1. The blends were then mixed
and grinded for 15 min using a mortar and pestle until homog-
enous mixtures were formed. The obtained powders were left
for 24 h at ambient temperature before further characterization.
2.11. Evaluation of liquisolid powders ﬂow properties
The ﬂow properties of the produced liquisolid systems were
evaluated by measuring the following parameters: angle of re-
pose, Carr’s index and Hausner’s ratio. The angle of repose (h)
was measured according to the conventional ﬁxed height cone
method.24 The powder was poured through a funnel with its
tip positioned at a ﬁxed height (H) until the apex of the conical
pile formed just reaches the tip of the funnel. The angle of re-
pose was calculated using the formula tan h= H/r where r is
radius of the pile of powder.
The Carr’s (compressibility) index and Hausner’s ratio were
calculated from the bulk and tapped density of the tested pow-
der.24 The powder was poured lightly into a 25 ml graduated
cylinder. The powder was tapped until no further change in
volume was observed. Powder bulk density, qb (g/cm
3), and
powder tapped density, qp (g/cm
3) were calculated as the
weight of the powder divided by its volume before and after
tapping, respectively. Percentage compressibility was com-
puted from the following equation:
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The Hausner’s ratio is calculated according to the following
equation: Hausner’s Ratio = volume before tapping/volume
after tapping. All tests were performed in triplicate and the
average was calculated for each powder.
2.12. In-vitro drug release studies
SSEDDS powders showing acceptable ﬂow properties were
studied for their in vitro drug release properties using USP
Apparatus I, using a 0.5 l mesh25 (rotating basket) (Hanson
SR8plus, USA). One gram of the tested powder was trans-
ferred to a 400 ml receptor medium which consisted of phos-
phate buffer pH 6.823,26–28 containing 15% methyl alcohol to
maintain sink condition at a speed of 100 rpm and the temper-
ature was maintained at 37 ± 0.5 C. At predetermined time
intervals (10, 20, 30, 45, 60, 90, 120 and 180 min), aliquots of
5 ml were withdrawn and replaced by fresh solution in order
to maintain sink condition throughout the experiment. The
withdrawn samples were ﬁltered through a 0.2 lm Millipore
membrane and then analyzed for drug content spectrophoto-
metrically at 367 nm. Release proﬁles were plotted and release
efﬁciency was calculated.29 The experiments were carried out
in triplicate and data were expressed as mean value ± S.D.
2.13. Characterization of selected liquisolid powder
2.13.1. Particle size and size distribution
The mean particle size and particle size distribution of the se-
lected liquisolid powder were performed by photon correlation
spectroscopy (Malvern Instrument Ltd., Worcestershire, Uni-
ted Kingdom). Before measurement, the sample was appropri-
ately diluted with double distilled water measured at 25 C
with an angle of detection of 90.
2.13.2. Scanning electron microscopy (SEM)
The surface characteristics of the selected liquisolid powder
were investigated by scanning electron microscope (SEM)
(JXA-840 A, JEOL, Tokyo, Japan). The sample was placed
on a clear glass stub and sputter-coated with a thin layer of
gold using a vacuum evaporator. SEM images were examined
using a SEM equipped with a digital camera, at 20 kV acceler-
ating voltage.
2.13.3. X-ray powder diffractometry (XRPD)
X-ray powder diffraction patterns of rutin, adsorbent and se-
lected liquisolid powder were recorded on a Diano X-ray dif-
fractometer (Scintag Inc., USA). Samples were irradiated
using Ni ﬁltered, CuKa radiation at a voltage of 45 kV, and
a 9 mA current. The scanning rate employed was 1 min1
over 0 to 90 diffraction angle (2h) range.
2.13.4. Fourier transform infrared spectroscopy (FT-IR)
Infrared spectra of rutin, adsorbent and selected liquisolid
powder were obtained using FT-IR spectrophotometer (Shi-
madzu 435 U-O4 IR spectrophotometer, Japan). Rutin, adsor-
bent and selected liquisolid powder were mixed separately with
IR grade KBr in the ratio of 100:1 and the corresponding disks
were prepared by applying a 5.5 metric ton of pressure in ahydraulic press. The disks were scanned over a wave number
range 4000–400 cm1.
2.14. Data analysis
All experiments were performed three times and the data were
expressed as mean ± standard deviation (S.D.). The statistical
signiﬁcance of differences was determined by ANOVA using
SPSS software (Version 17, Chicago). A value of p< 0.05
was considered to be signiﬁcant.
3. Results and discussion
3.1. Screening study
Drug loading per formulation is a critical design factor which
can be dependent on its solubility in various formulation com-
ponents.21 Drug may be solubilized in the oily core and/or on
the interface of these structures, so the selected vehicles should
have a good solubilizing power to the drug.30 Therefore, the
solubility of rutin in individual system components (oil, surfac-
tant, and co-surfactant) was tested for proper component
selection for ternary phase diagram study, and the results are
presented in Table 1. As a preformulation step, drug solubility
in different components was determined visually till no drug
crystals were detected indicating that it was dissolved.20 Start-
ing with the oily phase, both long and medium chain triglycer-
ide oils with different degrees of saturation were screened.
Based on the obtained data, oleic acid (OA) as well as Labra-
fac (Labc) showed the highest drug solubilizing effect (least
amount needed to dissolve the drug) and therefore were chosen
for ternary phase diagram study. The best solubilizing effect of
oleic acid was previously reported.31,32 Labc is a medium chain
fatty acid ester having a low HLB value (2) and can be used as
an oily vehicle in oral formulations especially self emulsifying
formulations, it’s good solubilizing effect for lipophilic drugs
was previously afforded.33,34 The selected oils for further inves-
tigations (OA and Labc) have fair ﬂuidity, proper self-emulsi-
ﬁcation properties and are efﬁciently digested.35 All other
tested oils showed poor rutin solubilizing power.
Concerning surfactants, Diacetin (glycerol diacetate)
which is known to be a good solvent,36 showed an excellent ru-
tin solubilizing effect. Similarly, Labrasol (Labl) having an
HLB value of 14 and composed of polyoxyethylene groups
which can interact with rutin showed high solubilization
capacity, similar high solubilizing properties of Labl were pre-
viously found for curcumin.34 Also, Triton X-100 (TX)
which is polyoxyethylene (POE) surfactant attained high drug
solubilization. The good wetting properties of TX for a hydro-
phobic drug were previously recorded37 and were attributed to
the structurally ‘‘linear’’ and short POE chains. Previous stud-
ies involving the solubilizing effect of TX include the solubili-
zation of clofazimine analogs,38 carbamazepine39 and
bromhexine hydrochloride40 by TX.
Regarding co-surfactants, ethanol (Eth), propylene glycol
(PG) and Acconon (AC) attained best drug solubilizing
properties. According to earlier reports,41 the co-surfactant
can lower the interfacial tension of the surfactant in
microemulsions, resulting in a more ﬂexible and dynamic layer.
The drug in this energy-rich system can diffuse across the
ﬂexible interfacial surfactant ﬁlm between the phases; a
Table 1 Screening of various components for rutin solubility.
Component Amount needed to
solubilize 10 mg rutin (gm)
Oil
Oleic acid 6.75 ± 0.354
Labrafac PG 7.50 ± 0.000
Isopropyl myristate 11.25 ± 1.768
Isopropyl palmitate 11.00 ± 1.414
Methyl Laurate >10
Miglyol 812 >10
Miranol >10
Surfactant
Diacetin 1.25 ± 0.354
Labrasol 2.75 ± 0.354
Capmul MCM C8 7.75 ± 1.061
Triton X-100 6.5 ± 0.707
Captex 200 >10
Plurol Oleique CC 497 >10
Labraﬁl M 1944 LS >10
Simulosol 1292DF >10
Co-surfactant
Ethanol 0.50 ± 0.000
PG 1.25 ± 0.354
PEG 400 2.50 ± 0.707
Acconon MC8 2.00 ± 0.000
Capryol 90 >10
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sion. It can decrease the ﬂuidity of SEDDS, enhances drug
incorporation into the SEDDS, improves self-emulsiﬁcation
properties, and possesses penetration enhancement effect.42
Also, it can reduce the required amount of surfactant.32
Therefore, different combinations of the following compo-
nents, OA and Labc (oils), Diacetin, Labl and TX (surfactants)
and Eth, PG and AC (co-surfactants) have been tested for their
potential to formulate successful self-emulsifying systems
(SEDDS) consisting of (S/CoS/oil) in a 80/10/10 ratio as a pre-
liminary study.
3.2. Assessment of self-emulsiﬁcation
SEDDS were prepared and their self-emulsifying properties
were visually observed, these systems should be a clear,
monophasic liquid when introduced into aqueous medium
and should have good solubilizing properties to present
the drug in a solution. Also, individual components should
have good miscibility with each other to produce a stable
formulation.26
The visual grading of the process of self-emulsiﬁcation
upon dilution as well as the composition of tested SEDDS is
shown in Table 2. It is obvious that only S1, S2, S3, S6 and
S7 presented type A and were selected for further investiga-
tion, namely, construction of ternary-phase diagram.
We can say that the S/CoS/oil combinations used to formu-
late the systems listed above increased the spontaneity of the
self-emulsiﬁcation process and the efﬁciency of emulsiﬁcation
was good, allowing spontaneous ﬁne emulsion formation. It
is well known that low particle size can allow the formation
of a more clear-appearing emulsion.433.3. Construction of ternary phase diagram
The existence of self-emulsifying oil formulation ﬁelds that
could self-emulsify under dilution and gentle agitation was
identiﬁed from ternary phase diagrams (Fig. 1) of systems con-
taining S/CoS/oil, the outer parallelogram indicates the loca-
tion of microemulsiﬁcation region. This can allow the
optimization of the oil, surfactant and co-surfactant concen-
trations used. In all cases, only compositions containing
610% oil were capable of self-emulsiﬁcation. This could be ex-
plained by the fact that the surfactant stabilizes the O/W inter-
face and its concentration increased at the interface upon
decreasing the oily content. Also, it is known that increasing
oil concentration increases particle size43 which opposes clear
emulsion formation.
It can be also observed that increasing S/CoS ratio in-
creased the probability of formation of successful SEDDS this
runs in parallel with some literature.44 The droplet size of the
emulsion is a crucial factor in self-emulsiﬁcation performance.
It was previously reported that increasing the surfactant con-
centration in the SEDDS formula decreased the particle diam-
eter of the emulsion formed which increases the probability of
SEDDS formation.45 The higher the proportion of surfactant
in the system, the greater is the spontaneity of emulsiﬁcation,
this may be due to excess penetration of aqueous phase into
the oil phase causing massive interfacial disruption and ejec-
tion of droplets into the bulk aqueous phase.42 Also, previous
reports indicated that the amount of CoS was inversely pro-
portional to emulsion stability.46
S2 composed of TX/Eth/OA showed the wider microemul-
sion area and isotropic regions and was capable of the forma-
tion of SEDDS with the S/CoS/oil ratio reaching 5/4/1. This
Table 2 Visual assessment of efﬁciency of self-microemulsiﬁcation and solubility of rutin in selected SEDDS (type A) at 37 C.
System Composition (S/CoS/oil: 80/10/10) Visual grade Rutin solubility (mg/ml)
S1 Triton/PG/OA A 0.380 ± 0.006
S2 Triton/Ethanol/OA A 0.295 ± 0.002
S3 Triton/AC/OA A 0.287 ± 0.036
S4 Triton/PG/Labrafac C –
S5 Triton/Ethanol/Labrafac C –
S6 Triton/Acconon/Labrafac A 1.444 ± 0.238
S7 Labrasol/Acconon/OA A 0.920 ± 0.0452
S8 Labrasol/Acconon/Labrafac D –
S9 Diacetin/Acconon/OA E –
S10 Diacetin/PG/OA E –
S11 Diacetin/Ethanol/OA E –
S12 Diacetin/Acconon/Labrafac E –
S13 Diacetin/PG/Labrafac E –
S14 Diacetin/Ethanol/Labrafac E –
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Figure 1 Ternary phase diagram of selected SEDDS (red boundries are indicating nanoemulsion regions).
266 R. Kamel, M. Bashacan be attributed to the presence of ethanol; a previous work
about microemulsion systems had shown that an ethanol co-
surfactant was necessary to maintain a stable single phase O/
W emulsion.47 Our results run in parallel with a previous study
showing that systems containing ethanol as CoS attained a
maximum area of microemulsion zone.483.4. Assessment of rutin solubility in the selected systems
Drug loading is a key factor for the selection of the suitable
formulation, a good balance between drug loading and efﬁ-
cient emulsiﬁcation is required. To judiciously comparebetween different type A systems, the common S/CoS/oil ratio
forming SEDDS in all cases which is 80/10/10, was applied
to formulate systems in order to investigate rutin solubility.
From Table 2, we can observe that S6, prepared from TX/
AC/Labc attained highest drug solubilization capacity
(p< 0.05). A proper justiﬁcation can be the good wetting
properties of TXP BS37 and the structurally ‘‘linear’’ and short
POE chains which can allow for a strong interaction with the
great number of free hydroxyl groups bared by the polypheno-
lic drug. The best solubilizing power of TX was previously
reported.38–40
TX is a nonionic surfactant with a high HLB value (17.6)
while, AC is a nonionic emulsiﬁer with a high HLB value
Preparation and in vitro evaluation of rutin nanostructured liquisolid delivery system 267too (14). Co-surfactants should be chosen for their poor afﬁn-
ity either with the continuous or the dispersed phase. The
proper co-surfactant will migrate to the oil/water interface
and form a mixed S/CoS ﬁlm. The CoS causes a transitory
lowering of the interfacial tension during the formation of
the dispersion.49 It is well known that a surfactant mixture
with higher HLB value is better for the formation of oil in
water nanoemulsions.50
The good solubility of the drug in the surfactant, CoS and
oil together with the proper S/CoS/oil combinations and the
high surfactant HLB value may be other causes of the highest
drug loading in S6. Therefore, this was the selected SEDDS for
characterization and for preparation of the solid SEDDS
(SSEDDS).
3.5. Characterization of selected SEDDS
The droplet size of the emulsion is a crucial factor in self-emul-
siﬁcation performance because it determines the rate and ex-
tent of drug release, as well as absorption. As shown in
Fig. 2, S6 possessed a small droplet size of 4.849 ± 0.001 nm
with a polydispersity index (PDI) of 0.14 ± 0.003 showing
monomodal droplet size distribution. This small droplet size
might be attributed to the higher S/CoS ratio as it was previ-
ously reported that increasing the surfactant concentration in
the SEDDS formula decreased the particle diameter of the
emulsion formed which increases the probability of SEDDS
formation.45 A small droplet size indicates a stable formulation
and rapid emulsiﬁcation.51
Similarly, a previous study has shown that the system con-
taining Labc, with a relatively short chain fatty acid, attained a
small droplet size.52 It is well known that the chain length of
the oil plays a role in the ease of emulsiﬁcation, stabilization
of the emulsions, as well as the emulsion droplet size.
Percentage transmittance of S6 after dilution for 100 times
with deionized water was 99.31 ± 0.16%, such transmittance
value having proximity to 100% indicates that clear nanoemul-0
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Figure 2 Droplet size and size distribution of S6.
Table 3 Classiﬁcation of ﬂow properties.54,55
Angle of repose (h) Hausner ratio (HR)
<30 <1.25
30–40 1.25–1.50
>40 >1.50sion was formed when SEDDS was diluted with deionized
water.
It was previously reported that, upon dilution, the two
phases of a conventional emulsion will tend to separate, in or-
der to reduce the interfacial area, and subsequently, the free
energy of the system. While, in the case of self-emulsifying sys-
tems, if the free energy required to form the emulsion is very
low, then, the emulsiﬁcation process occurs spontaneously.53
3.6. Preparation and evaluation of liquisolid powders ﬂow
properties
Self-emulsifying powder was prepared to overcome the disad-
vantages associated with liquid SEDDS. Hence, to increase the
stability and patient compliance the selected formulation, S6,
was adsorbed onto different adsorbents at various carrier
loads. However, speciﬁc carriers are required to allow obtain-
ing the powder having superior ﬂowability properties. The
classiﬁcation of ﬂow properties based on ‘‘angle of repose’’,
‘‘Carr’s index’’ and ‘‘Hausner ratio’’ is listed in Table 3.54,55
S6 was adsorbed to several new carriers, namely, Neusilin,
Fujicalin and F-melt type M, these have a nano-structure
allowing for high adsorption properties.As shown in Table 4,
eleven SSEDDS were produced where the SEDDS: carrier ra-
tio was varied from 3:1 to 1:3 or until reaching a cohesive pow-
der mass which cannot be evaluated for its ﬂow properties. The
carrier as well as ratio variation was aiming to attain a free
ﬂowing powder having a high drug loading capacity. The latter
was quantiﬁed using the following equation56:
Lf ¼W=Q
where, Lf is the liquid loading factor; W is the liquid medica-
tion (SEDDS) weight; Q is the carrier material weight.
F-MELT is a co-spray dried excipient. It could be a prop-
er strategy to improve the quality, performance and provide
taste masking of solid oral dosage forms.16,57
Fujicalin is a spray-dried second generation dibasic cal-
cium phosphate anhydrous (DCPA) offering a new grade of
DCPA with unique properties. With a typical voided card-
house structure, Fujicalin has signiﬁcantly higher speciﬁc
surface area and higher oil adsorption capacity than conven-
tional DCPA. Fujicalin particle’s structure has high porosity;
it retains 2 to 3 times higher porosity than other popular excip-
ients. With its spherical shape and smooth surface, Fujicalin
is highly ﬂowable and has excellent blending capacity which in-
creases drug content uniformity of obtained formulations and
reduces variation.
Neusilin is a spray-dried totally synthetic, amorphous
form of magnesium aluminometasilicate (MAS) that can be
used both in pharmaceutical and cosmetic preparations. It
has also been demonstrated as an excellent adsorbent carrier
for solid dispersion and SEDDS58 by simple mixing ofCarr’s index (CI) Flow properties
<15 excellent
15–25 good
>25 poor
Table 4 SSEDDS ﬂow properties.
Formula Carrier Carrier: SEDDS ratio h HR CI Lf**
Rutin – – – – – –
SS 1 3:1 18.43 ± 0.22 1.14 ± 0.01 12.50 ± 0.64 0.33
SS 2 Neusilin US2 2:1 20.12 ± 0.25 1.18 ± 0.01 17.94 ± 0.86 0.50
SS 3 Properties*
a = 300
b = 2.7–3.4
c =2.4–3.1
1:1 20.45 ± 0.24 1.20 ± 0.02 18.55 ± 0.54 1.00
SS 4 1:2 24.33 ± 0.30 1.31 ± 0.01 22.92 ± 0.29 2.00
SS 5 1:3 29.65 ± 0.21 1.34 ± 0.02 24.30 ± 0.51 3.00
SS 6 Fujicalin 3:1 24.86 ± 0.19 1.23 ± 0.01 24.92 ± 0.34 0.33
SS 7 Properties*
a = 40
b = 1.1
c = 1.2
2:1 26.56 ± 0.21 1.33 ± 0.02 25.08 ± 0.44 0.50
SS 8 1:1 37.35 ± 0.26 1.51 ± 0.02 33.07 ± 0.39 1.00
SS 9 1:2 – – – 2.00
SS 10 F-melt (M) 3:1 44.30 ± 0.22 1.81 ± 0.03 42.60 ± 0.70 0.33
SS 11 2:1 – – – 0.50
* a: Speciﬁc surface area (m2/g),16,17 b: Oil adsorption capacity (ml/g), c: Water adsorption capacity (ml/g).
** Lf: loading factor.
268 R. Kamel, M. Bashacrystalline drug and Neusilin. Fuji’s Neusilin comes with
high speciﬁc area, increased surface adsorption, porosity, anti-
caking and ﬂow enhancing properties.17 These features of
Neusilin allow formulators to explore liquisolid technology
to improve bioavailability and overcome problems associated
with processing and stability of poorly water soluble drugs.59
The physical and chemical stability of the amorphous state
of drug-Neusilin complexes is well documented.
Table 4 shows the ﬂow properties and Lf of all formulated
SSEDDS, it is obvious that SS9, SS11 as well as the drug pow-
der itself were too cohesive to pass through the evaluation pro-
cess. It can be detected that Neusilin seems to be the best
carrier allowing for the highest Lf (Lf for SS5 = 3) as well
as good ﬂow properties. On the other side, F-melt did not
show satisfactory results, as the formulated powder had poor
ﬂowability although having low drug loading capacity
(Lf = 0.33). Fujicalin showed intermediate results with SS8
having an Lf equal to 1 but showing slightly poor ﬂowability,
while SS9 (Lf = 0.5) had good ﬂowability.
The previous results could be expected and are due to some
differences in physical properties of the three tested carriers. F-
melt has poor adsorption capacity, hence, is not suitable for
liquisolid preparation, while both Fujicalin and NeusilinFigure 3 In vitro release proﬁles of rseem to have physical properties16 (Table 4) encouraging their
use for it.
Powders having poor ﬂow properties, namely SS8 and SS10
(according to Table 3) were excluded from further investiga-
tion concerning the release of drug from formulated liquisolid
powders. In addition, ﬂowable powders allowing for higher Lf
values were preferred. Although SS6 has slightly better ﬂow
properties when compared to SS5 (p> 0.05), its Lf value
was too low. Therefore; only SS3, SS4, SS5 and SS7 were sub-
jected to release study.
3.7. In-vitro drug release studies
The aim of our study was to improve rutin dissolution as well
as ﬂow properties. It is well known that SEDDS improve the
oral bioavailability of poorly soluble drugs by improving the
solubility and maintaining the drug in small droplets of oil,
all over the gastrointestinal tract.42 As well, liquisolid powder
of poorly soluble drugs provides enhanced drug release due to
its ability to adsorb the drug on its high surface area and thus
improves drug wettability.60 Accordingly, this optimized drug
release allows improved drug absorption and thus higher oral
bioavailability.61utin from SEDDS (Mean ± SD).
Preparation and in vitro evaluation of rutin nanostructured liquisolid delivery system 269It is obvious from Fig. 3 that all SSEDDS containing
Neusilin (SS3, SS4 and SS5) showed far better release from
that of Fujicalin (SS7) (p< 0.05), this may be due to the dif-
ference in physical properties between both, favoring the better
release properties of Neusilin. The latter has a higher speciﬁc
surface area and water adsorption capacity compared with the
former (Table 4) which allows a facilitated wetting of drug-
loaded particles and improved drug release from the SSEDDS.
Regarding the Neusilin group, SS4 had the best drug re-
lease properties which can be seen in the release proﬁles and
attained the highest release efﬁciency value (p < 0.05)
(Fig. 2). This can be explained by the higher drug loading
(Lf) compared to SS3, which increases drug concentration in
the preparation and consequently increases the concentration
gradient. The latter is an important release driving force. Fur-
ther increase in drug loading (SS5) was not accompanied by
improved release; this may be due to highly decreased ﬂow
properties (Table 4) and thus, particles aggregation. On the200 nm
Figure 4 Scanning electro
Figure 5 X-ray patterns of (a) rother hand, the higher Carr’s index (p< 0.05) of SS4 com-
pared to SS3 may be an indication of higher porosity of the
former.54,55 Increased porosity can allow rapid ingress of the
dissolution medium inside the particles and facilitate drug dif-
fusion out, resulting in a faster drug release.
3.8. Characterization of selected liquisolid powder
3.8.1. Particle size, size distribution and scanning electron
microscopy (SEM)
Particle size analysis of the selected SSEDDS (SS4) demon-
strated a monodisperse system with a mean diameter of
255.00 ± 0.001 nm having a polydispersity index (PDI) of
0.10 ± 0.001 indicating homogenous distribution.
Fig. 4 shows the scanning electron micrographs of SS4. The
micrographs revealed that the solid SEDDS powder appeared
as well separated almost spherical particles having nearly the
same particle size obtained by size analysis. No separated100 nm
n micrographs of SS4.
utin, (b) Neusilin and (c) SS4.
Figure 6 FT-IR spectra of (a) rutin, (b) Neusilin and (c) SS4.
270 R. Kamel, M. Bashacrystals were observed on the surface of the particles. The por-
ous structure and small particle size of the carrier can allow the
drug-loaded liquid SEDDS to be entrapped in the core or ad-
sorbed on the surface. Upon contact with an aqueous phase,
rapid ingress of the latter into the matrix can be guaranteed,
the liquid SEDDS will be rapidly transformed into o/w nano-
emulsion, thus making rutin ready for absorption.
3.8.2. X-ray powder diffractometry (XRPD)
The XRPD patterns of rutin, Neusilin and SS4 are shown in
Fig. 5. Rutin showed sharp intense peaks, the most character-
istic one was recorded at 2-theta value of 26.27 demonstrating
the crystalline nature of the drug (Fig. 5a). On the other hand,
Neusilin appeared amorphous as it did not show any distinc-
tive peaks over the entire range of the tested temperatures
(Fig. 5b). As illustrated in Fig. 5c, the peaks of rutin were com-
pletely absent in SS4 indicating the transformation of rutin to
the amorphous form in the SSEDDS.
3.8.3. Fourier transform infrared spectroscopy (FT-IR)
Fig. 6 illustrates the FT-IR spectra of rutin, Neusilin and SS4.
Pure rutin exhibits an obvious characteristic ﬁngerprint in the
region 1500–400 cm1. Characteristic bands of rutin can be
observed at 3424.96 cm1 (OH stretch), 2929.34,
2911.99 cm1 (C-H stretch), 1655.59 cm1 (C‚O stretch)
and 1600.63 cm1 (aromatic structure) (Fig. 6a). These peaks
have appeared in case of SS4 (Fig. 6c) shifted at 3448.1 cm1
(OH stretch), 2927.41 cm1, 2881.13 cm1 (C-H stretch),
1738.51 cm1 (C‚O stretch) and 1617.02 cm1 (aromatic
structure). These positional as well as morphological changes
in the peaks can prove the physical and/or ionic interactionoccurring between the different components and the complete
incorporation of the drug within the SEDDS.
4. Conclusion
We can conclude that, in this study, a number of promising
self-emulsifying formulations were identiﬁed and loaded on re-
cent nano-structured carriers. The SEDDS composed of Tri-
ton/Acconon/Labrafac adsorbed on Neusilin in a 2:1 ratio
showed good ﬂow properties and best drug release, proving
that delivering the drug in a solubilized and rapidly dispersed
manner can be achieved through rational design of lipid-based
formulations. The designed liquisolid or solid self-emulsifying
powder can provide a promising strategy for the formulation
of poorly aqueous soluble lipophilic compounds like rutin.
5. Conﬂict of interest
None.
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